Combination of the Vaginal Laser With a Moisturizing and Repairing Niosomal Gel in the Treatment of Genitourinary Syndrome in Oncology Patients

Combinación Del láser Vaginal Con un Gel Niosomal Hidratante y Reparador en el Tratamiento Del síndrome Genitourinario en Pacientes oncológicas

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06508788

Enrollment

Registered

2024-07-18

Start date

2024-07-01

Completion date

2026-07-01

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Syndrome of Menopause

Keywords

Genitourinary Syndrome of Menopause, CO2 laser

Brief summary

Vaginal laser together with the use of moisturizing and repairing gels could be an effective therapy for the treatment of genitourinary syndrome in women with a history of neoplasia in whom the use of estrogens is not recommended. The purpose of this study is to evaluate the effectiveness of vaginal laser together with adjuvant treatment with a hydrating and repairing niosomal gel as a beneficial treatment in this group of patients.

Interventions

DEVICECO2 laser

Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with an established SGM diagnosis. * Patients with a history of neoplasia in whom the use of estrogens as the first alternative for the treatment of GMS is not recommended.

Exclusion criteria

* Patients with concomitant vulvovaginal pathology. * Patients with a diagnosis of pelvic organ prolapse grade II or greater.

Design outcomes

Primary

Measure	Time frame	Description
Effectiveness	12 months	To evaluate the effectiveness of CO2 vaginal laser together with adjuvant treatment with a hydrating and repairing niosomal gel as a beneficial treatment in patients with a history of neoplasia in whom the use of estrogens is not recommended

Secondary

Measure	Time frame	Description
Security	12 months	To determine the safety (side effects) of vaginal laser therapy
Duration	12 months	To determine the durability of the effects produced by vaginal laser therapy

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026